Company intelligence / Profile preview
IHP Therapeutics
San Carlos, California, United Statesihptherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
IHP Therapeutics is developing novel therapeutics including IHP-102, a dual P-selectin and complement inhibitor for sickle cell disease, and IHP-101 for solid tumors. The company also has IHP-009, a Phase 3 ready molecule for COVID-19 treatment.
- Therapeutic areas
- OncologyInfectious DiseasesHematology
- Modalities
- Small molecule drugGlycans
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on IHP Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IHP Therapeutics.